Headline News

 

Sanofi’s Sarclisa subcutaneous formulation wins approval in Japan for patients with multiple myeloma

Posted on June 22, 2026

Pfizer reports topline Phase 3 findings for sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer

Posted on June 22, 2026

TALVEY plus DARZALEX FASPRO data highlights the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Posted on June 16, 2026

Moderna receives UK authorization to begin Phase 1/2 study of investigational mRNA cancer vaccine for people with Lynch syndrome

Posted on June 16, 2026

Zepbound and Shaquille O’Neal launch national campaign after NBA legend discovers the obstructive sleep apnea he has lived with for years can be treated

Posted on June 16, 2026

Lilly’s Jaypirca cuts risk of disease progression or death by 45% when paired with a time-limited venetoclax regimen in previously treated CLL/SLL

Posted on June 16, 2026

Truqap combination wins US approval as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Posted on June 16, 2026

Ultomiris secures Priority Review in the US for treatment of adults with immunoglobulin A nephropathy

Posted on June 16, 2026

Sanofi shares update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Posted on June 16, 2026

Sanofi’s Tzield receives US approval as the first disease-modifying therapy for patients newly diagnosed with stage 3 type 1 diabetes

Posted on June 16, 2026

FDA grants Priority Review to Roche’s Tecentriq for a specific form of stage III colon cancer

Posted on June 16, 2026

Roche secures FDA approval for first companion diagnostic to detect PTEN protein status in prostate cancer patients

Posted on June 16, 2026

Roche enters global collaboration with Nurix Therapeutics to jointly develop and commercialise BTK degrader bexobrutideg across blood cancers, immunology and neurology

Posted on June 09, 2026

Novartis set to present Rhapsido data across a range of immune-mediated diseases at EAACI Congress 2026

Posted on June 09, 2026

Phase 2b data backs monthly dosing potential for Pfizer’s GLP-1 RA berobenatide with strong efficacy and tolerability findings

Posted on June 09, 2026